Auris Medical nabs new patent in Europe; shares up 12% premarket – Auris Medical Holding Ltd. (NASDAQ:EARS)

Auris Medical Holding (NASDAQ:EARS) is up 12% premarket on receiving a notice of “Intention to Grant” from European Patent Office (EPO) for its patent application entitled “Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System” (Application 11 894 529.3).

The allowed claims cover compounds modulating the sodium potassium chloride co-transporter 1 for use in the oral treatment or prevention of tinnitus.

Source link